ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets close in 4 hrs 11 mins

Alnylam Pharmaceuticals, Inc. (ALNY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
53.10-0.15 (-0.28%)
As of 11:48AM EDT. Market open.
People also watch
BMRNACORSGENACADALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close53.25
Open53.21
Bid53.24 x 200
Ask53.33 x 200
Day's Range52.40 - 53.94
52 Week Range31.38 - 80.11
Volume237,591
Avg. Volume1,020,768
Market Cap4.57B
Beta3.51
PE Ratio (TTM)-11.08
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks6 hours ago

    Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?

    Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Could Biogen Spinoff Bleed This Biotech In Hemophilia?
    Investor's Business Daily19 hours ago

    Could Biogen Spinoff Bleed This Biotech In Hemophilia?

    Alnylam's fitusiran will pull in $989 million in 2025, but won't launch until 2020 amid competition with Biogen spinoff Bioverativ.

  • American City Business Journals3 days ago

    ​Alnylam CEO’s pay fell nearly 80 percent in 2016

    The CEO of Alnylam Pharmaceuticals saw his compensation drop precipitously in 2016 as the Cambridge biotech lost about half of its market value, according to a federal filing. John Maraganore received about $1.7 million in total compensation in 2016, down from nearly $8.3 million in 2015, a decrease of nearly 80 percent, according to the filing on Friday. The filing shows that Maraganore realized nearly $4.9 million in value by exercising options in 2016.